PeptideFactSheetsAn independent reference
Menu
Plain-English comparison

Peptides for muscle growth and performance: what human evidence shows

Why growth-hormone signals, mitochondrial biology, and body-composition claims do not automatically prove more muscle, strength, recovery, or performance.

Published by PeptideFactSheets. Sources and methods · Research reporting, not clinical review.

Overview

Muscle and performance marketing often treats a rise in growth hormone, IGF-1, or a mitochondrial marker as if it were proven muscle gain or better athletic function. Those are different endpoints.

GHRP-2, CJC-1295, and ipamorelin can affect hormone signaling but are not FDA approved for muscle growth. Tesamorelin's approval is limited to excess abdominal fat in adults with HIV and lipodystrophy. MOTS-c remains largely preclinical, while elamipretide has a narrow Barth syndrome muscle-strength indication.

Side-by-side comparison

GHRP-2
Not FDA approvedEarly human evidence

Studied for

Growth-hormone release · Appetite and food intake · Endocrine testing and physiology

CJC-1295
Not FDA approvedEarly human evidence

Studied for

Growth hormone and IGF-1 levels · Pharmacology and tolerability

Ipamorelin
Not FDA approvedEarly human evidence

Studied for

Growth hormone release · Gastrointestinal motility · Postoperative ileus

Tesamorelin
FDA approved for specific usesStrong human evidence for approved uses

Studied for

HIV-associated lipodystrophy · Visceral abdominal fat · Metabolic measures

MOTS-c
Preclinical researchMostly animal or lab research

Studied for

Insulin sensitivity and metabolic regulation in animal models · Exercise adaptation and physical capacity · Age-related metabolic decline

Elamipretide
FDA approved for specific usesModerate human evidence

Studied for

Barth syndrome · Primary mitochondrial myopathy · Mitochondrial function and muscle energetics

Approved versus investigational

An FDA approval means the agency reviewed evidence for a specific product, population, and use. It does not validate other molecules in the same family or uses outside the label. “In Phase 3” still means investigational.

Research areas

  • Growth hormone and IGF-1 signaling
  • Body composition in narrowly defined medical populations
  • Mitochondrial muscle energetics
  • Strength, recovery, and physical-function outcomes

Risks

  • Hormone release and biomarker changes are not validated muscle, strength, or performance outcomes.
  • Narrow rare-disease or HIV-lipodystrophy approvals do not validate use in healthy athletes or for bodybuilding.
  • FDA identifies significant evidence and safety gaps for compounded GHRP-2, CJC-1295, ipamorelin, and MOTS-c.

Open questions

  • Whether the unapproved peptides produce meaningful strength or function gains
  • Long-term endocrine, glucose, cardiovascular, immune, and product-quality risks
  • Safety and effects of combinations promoted online

Questions to ask a healthcare professional

1. Did the study measure muscle mass, strength, function, or only a hormone level?

2. Was the population healthy, injured, critically ill, or living with a rare disease?

3. Is the exact product approved for this use?

4. Were benefits large enough to matter and accompanied by adequate safety follow-up?

Summary

Hormone and mitochondrial signaling changes do not establish strength or function gains. The unapproved peptides in this group have no established bodybuilding or performance indication.

CompareGrowth hormone pathway peptides comparedHow tesamorelin, sermorelin, CJC-1295, and ipamorelin differ in mechanism, status, and evidence.CompareMitochondrial peptides comparedHow FDA-approved elamipretide differs from preclinical MOTS-c and Humanin research in status, evidence, muscle claims, and healthy-aging hype.ComparePeptides for recovery: what evidence exists?What the evidence says about BPC-157, thymosin beta-4, CJC-1295, and ipamorelin for injury recovery.

Sources

  1. fdaFDA: selected compounded-peptide safety risks

    FDA evidence gaps and potential risks for GHRP-2, CJC-1295, ipamorelin, and MOTS-c.

  2. pubmedGHRP-2 hormone and appetite study

    Small physiology study that did not test muscle growth or performance.

  3. fdaFDA prescribing information: Egrifta SV

    Narrow tesamorelin indication and explicit limits on general weight-management claims.

  4. pubmedMMPOWER-3 randomized trial

    Phase 3 mitochondrial myopathy trial that did not meet walking-distance or fatigue endpoints.